Guardant Health appoints Myrtle Potter to Board of Directors

Guardant Health, Inc.

Myrtle Potter appointed as Class I director effective Oct 15, 2021; term expires at 2022 Annual Meeting.
Potter also appointed to audit committee; will receive standard non-employee director compensation.
Compensation includes stock option and RSU each valued at $362,500 with modified grant date Nov 8, 2021.
Awards vest 1/4 on first anniversary of appointment, then monthly over three years.
Potter is CEO of Sumitovant Biopharma; previously COO at Genentech and President at Bristol-Myers Squibb.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Myrtle Potter

Class I director

GH · Guardant Health, Inc.

Effective: 2021-10-15
Filed: October 20, 2021, 7:59 PM ET

Effective October 15, 2021, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Myrtle Potter as a Class I director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Myrtle Potter was appointed as Class I director at Guardant Health, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

Effective October 15, 2021, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Myrtle Potter as a Class I director of the Company.

View on SEC.gov

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-303088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.